A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.

Visit SirenInteractive.com to learn more.

Please email Frieda Hernandez for inquiries for more information.

Adventures in eMarketing

Sign up for the monthly enewsletter to receive:

  • The latest pharma and interactive trends
  • Insight into building relationships with rare disease communities
  • The latest news in health care, marketing and the internet
  • Thought-leadership you can’t afford to miss
View a sample newsletter Sign Up for
Adventures in eMarketing

#SocPharm on Twitter

socpharm twitter badge

#SocPharm is a weekly chat on Twitter about pharma marketing and social media. Read a transcript below or learn how to join in.

See past #SocPharm transcripts Learn how to join weekly
#SocPharm chats

Blog Roll

Tag Cloud

#SocPharm Tweetchat Transcript 2/9/2011

Posted by Eileen O'Brien | 10:26 pm on Wednesday February 09, 2011 | No Comments

Share this article:

:
Excited that @ formerly of AZ, now consulting, will be guest moderating #socpharm tonight so I can relax w/my wine :) #socpharm

:
#socpham Welcome to the pharma marketing & social media chat (#socpharm). Please start w/intro & why you’re interested in the topic.⁰⁰

:
@ @ Anyone that thinks social media is going to save DTC marketing is kidding themselves #hcsm #socpharm

:
#socpharm We’ll assume that all tweets within #socpharm are your own and not your employers (unless you specifically declare them).⁰⁰

:
Hi Earl! I’m Eileen work at Siren Interactive, focus on #raredisease therapies. Interested in all things #epharma #pharma #socpharm….

:
This is hard without Tweetdeck! It won’t let me connect on home computer & Tweetchat is waaay delayed. #socpharm

:
Happy to guest moderate tonight. #socpharm

:
T1 Pharmacos talk about shift from product-centric to patient and customer centric. I see great implications for SM engagement #socpharm

:
@ I wonder if everyone in pharma marketing is at #epharma in NYC all out at dinner now :) #socpharm

:
T1: Agree it’s a great shift from a brand-focus to a focus on patients/caregivers (& always HCPs). #socpharm

:
Your opinion on Pharma Content: What is appropriate vs. what is permissible? #socpharm

:
@ Can you clarify that question a bit? #socpharm

:
@ Who said anything about “save”? Basic, fact-of-life, no-brainer, better-figure-it-out stuff. @ #hcsm #socpharm

:
RT @ @ is on fire re: FDA no-action on SM guidelines. http://bit.ly/efw0Qs #hcsm #socpharm

:
DDMAC likely to give basic guidance only and not meet pharmaco expectaion. What should pharmacos do? #socpharm

:
RIch Meyer World of DTC Marketing & writer for various med and marketing pubs #socpharm

:
@ Hi Rich!! #socpharm

:
@ What pharma should’ve been doing all along: basics. Listening via sm, creating employee guidelines, educating themselves #socpharm

:
@ Still many ways to stay within current FDA guidelines & participate in social media #socpharm

:
Hi #socpharm, Brent from DSI here…took me a minute to get the tech working…

:
Agreed – lay the groundwork: RT @: @ What pharma should’ve been doing all along: basics. #socpharm

:
drink! RT @: @ Still many ways to stay within current FDA guidelines & participate in social media #socpharm

:
Warning getting on soapbox: pharma should do web basics 1st before worrying abt sm. Ensure organic & paid search r good #socpharm

:
@ LOL! I do have a lovely glass of Shiraz sitting next to me, so I will drink #socpharm

:
@ Haven’t read all the #epharma tweets. What’s the hot topic? #socpharm

:
Good evening everyone;-) #socpharm

:
@ mobile was especially hot this year #socpharm

:
Basics are very impt and all co’s should be engaging at that level. So why aren’t they? #socpharm

:
@ Hello! We are talking about the shift in pharma marketing from brand to patient focus. #socpharm

:
@ Shiny object syndrome? Silos? #socpharm

:
Lots of pharma comps will not allow employees to monitor SM because of Adverse events #socpharm

:
@ Still? Will those pharmacos allow agencies to monitor SM & report AEs through normal channels. #socpharm

:
#socpharm @ & I thght there was a gd mix betwn soc, mobil and some back 2 basics stuff. (a good basics prez frm @)

:
It depends on the company I know 2 here on West Coast that wont even allow employees to go to SM sites #socpharm

:
@ Do you mean they don’t allow employees to monitor SM just at work or also privately? #socpharm

:
@ No they do not hell they wont even sponsor an patients advocate group because they cant control content #socpharm

:
Wow, I thought we were past that & that pharma understood the value of listening via sm. #socpharm

:
@ It’s a pharma job- not the FBI. They shouldn’t have that much control over employees’ private lives. #socpharm

:
Depends on legal risk comfort. Pharmacos only shoudl be respons for AE reporting on their own co or brand sites / properties #socpharm

:
@ One company even blocks BLOGGER sites from Google #socpharm

:
RT @ @ I dont think its that simple yet….unfortunately #socpharm

:
RT @: My friend @ is on fire re: FDA no-action on SM guidelines. http://bit.ly/efw0Qs #hcsm #socpharm

:
@ Sadly not for some companies #socpharm

:
RT @: @ It’s a pharma job- not the FBI. They shouldn’t have that much control over employees’ private lives. #socpharm

:
See, I always learn something new on the #socpharm tweetchat. And I’ve even had my laugh thanks to @!

:
T2 Do patients care more about sat /loyalty to a product, trust in a co., or their network’s experience w a company or iproduct? #socpharm

:
@ @ A friend who works in Pharm cannot write my LinkedIn recommend since it’s against SocMed policy! #socpharm #FYI

:
@ @ Yes and a biotech company out here terminates people who write on social media boards #socpharm #FYI

:
T2 Do patients care more about sat /loyalty to a product, trust in a co., or their network’s experience w a company or product? #socpharm

:
@ Interesting questionl For pharma I think it depends on drug. If they are happy w/drug no burning need to change. #socpharm

:
@ what do you mean by “network” #socpharm

:
RT @: T2 Do patients care more about sat /loyalty to a product, trust in a co., or their network’s experience w a company or product? #socpharm

:
T2 If pt having side effects will trust network experience with product IMHO #socpharm

:
@ The network you operate in – your FB friends, Twitter followers, bloggers you read etc. #socpharm

:
T2 I would guess it’s strongest with their personal networks – friends & family. Some prob don’t know what cos make their Rx’s. #socpharm

:
@ thanks #socpharm

:
@ @ That’s crazy! #socpharm

:
RT @ @: My friend @ is on fire re: FDA no-action on SM guidelines. http://bit.ly/efw0Qs #hcsm #socpharm

:
@ I would agree…network trust is usually pretty strong. But if someone has good first hand exp, that is key #socpharm

:
funny because pharma hardly ever does market research with current patients to ask them the trigger for trial its always target #socpharm

:
so pharma legal and reg OK’s the stuff they have been fined for like off label promo but not social media ??? #socpharm

:
@ @ Just sayin’: #LinkedIn is hardly a socmed board. #socpharm A public recommendation of personal friend: Nix.

:
T2 For serious meds (ie cancer) probably doctor reco is key. But for allergy, birthcontrol etc. family/friends may be essential #socpharm

:
@ I think the future will rely more on payer insight than patient #socpharm

:
ePharma summit, DDMAC & Social Media and other musings | World of DTC Marketing.com http://t.co/Wje7l5R #socpharm

:
RT @: @ It’s a pharma job- not the FBI. They shouldn’t have that much control over employees’ private lives. #socpharm

:
RT @: @ One company even blocks BLOGGER sites from Google #socpharm // I smell fear.

:
@ It certainly depends on the d state. Also depends on timeline. Sometimes research happens after trial #socpharm

:
Reality: Lots of big brand coming off patent =lots of people looking for new jobs #socpharm

:
T3 F/U to T2. Does Co reputation influence medicine choice with patients? #socpharm

:
@ Patients should fear payers a lot more than pharma #socpharm

:
@ Interesting point about the key role payers play. #socpharm

:
@ I don’t think this happens as much as the industry would like to think #socpharm

:
Pharma is also going to have a hard time attracting new blood & talent #socpharm

:
@ US Rx market is low single digit growth for teh next 4-5 yrs. Many big pharmacos dealing with negative growth. #socpharm

:
Is this more relevant among HCP customers? RT @: T3 F/U to T2. Does Co reputation influence medicine choice with patients? #socpharm

:
@ Yes and a good time for new business models and investment in infrastructure by asking what do we need in 5 years #socpharm

:
where should pharma start 2 look? RT @: Pharma is also going to have a hard time attracting new blood & talent #socpharm

:
@ Good question. I do think patients can influence Phys decisions on Rx. #socpharm

:
@ Digital” They need people who understand marketing and digital channel and how people using #socpharm

:
@ Agree Rich #socpharm

:
@ They also need to invest in infrastructure for digital marketing #socpharm

:
@ Hell they dont even get the money they are loosing through non compliance #socpharm

:
@ I agree too. But its hard to get digital talent to pharma. Who wants a big slice of frustration? #socpharm

:
@ Exactly nobody in their right mind wants to work in pharma now #socpharm

:
@ Anyone can use SM to market basic consumer goods, it takes someone who likes a challenge & has smarts to do pharma! #socpharm

:
@ @ There are digital evangelists within pharma. They need to be supported and encouraged by their co’s. #socpharm

:
@ note to self…update resume…consider new trade…#socpharm

:
From what I am seeing now the market is real hot for digital marketing talent so why would anyone want to go to pharma ? #socpharm

:
@ @ Yes but they dont want to rock boat too much cause they live in fear #socpharm

:
stability? oops,newermind…RT @ @ @ Yes but they dont want to rock boat too much cause they live in fear #socpharm

:
@ It’s a fascinating space w/a unique challenge & potential to make a difference. Who wouldn’t want to? #socpharm #Idrankcoolaid

:
@ Some yes but not all. Some hit the speaking circuit and some are successful getting their execs engaged. #socpharm

:
What we do is so damn important to people and yet we’re consistently fighting city hall for basics #socpharm

:
@ Dont get me started on the people from agencies that hit speaking when they should be doing instead of talking #socpharm

:
Big thanks to @ for guest moderating tonight. I’ll let you know when I post the transcript. #socpharm

:
Thanks everyone for the great convo! Lots to think about about and ponder… :) #socpharm

:
@ No we need to be the voice of people who want help making healthcare choices #socpharm

:
Ok #socpharm, need to end on a high note…youre bringing me down!

:
FDA approves radiology app for doctors — http://bit.ly/fdgvaV #fdasm, #epharma, #socpharm

:
if pharmacos are patient centered then they have a responsibility to engage. Otherwise their patients suffer. #socpharm

:
@ Those people who are not passionate #socpharm #Idrankcoolaid

:
Gnite #socpharm we live to fight another day…

:
Going from #socpharm chat right into #dsma chat!

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media, and has been invited to speak at industry conferences and quoted in publications. As @eileenobrien she moderates the #SocPharm tweetchat the first Wednesday of every month at 8 pm ET which discusses pharma marketing and social media. She can also be found on Google+.

View other posts from Eileen

Share this article:

  • Facebook
  • Twitter
  • LinkedIn

Post a comment:

Twitter Users
Enter your personal information in the form or sign in with your Twitter account by clicking the button below.

Recent Posts